Science Explorer Back to mapMap
Discussion
Institution · Octapharma (United States)

Most cited papers from Octapharma (United States)

Octapharma (United States)

What are the most cited papers from Octapharma (United States)?

The most cited paper from Octapharma (United States) is "Interference of Maltose, Icodextrin, Galactose, or Xylose with Some Blood Glucose Monitoring Systems" (Thomas G. Schleis, 2007), with 102 citations. Next come "The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics" (89) and "Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery" (58).

Showing 50 of 80 papers. Every paper with more than 0 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Interference of Maltose, Icodextrin, Galactose, or Xylose with Some Blood Glucose Monitoring Systems Thomas G. Schleis · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy 27 Aug 2007 102
2 The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics Elisabeth Casademunt, Kristina Martinelle, Mats Jernberg et al. · European Journal Of Haematology Open access 13 Jun 2012 89
3 Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery Keyvan Karkouti et al. · JAMA Open access149 authors 29 Mar 2025 58
4 Minocycline HCl Microspheres Reduce Red‐Complex Bacteria in Periodontal Disease Therapy J. Max Goodson, John C. Gunsolley, Sara G. Grossi et al. · Journal of Periodontology Aug 2007 56
5 Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy Jane Elizabeth Rogers, Ryan M. Bolonesi, Asif Rashid et al. · Journal of Gastrointestinal Oncology Open access Apr 2017 50
6 Mechanical Therapy With Adjunctive Minocycline Microspheres Reduces Red‐Complex Bacteria in Smokers Sara G. Grossi, J. Max Goodson, John C. Gunsolley et al. · Journal of Periodontology 31 Aug 2007 50
7 Barriers to care and quality of primary care services in children with sickle cell disease Eufémia Jacob, Courtney Childress, Joana Duran · Journal of Advanced Nursing Open access 15 Sep 2015 41
8 Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency Cecil Reuben Ross, S. Rangarajan, Mehran Karimi et al. · Journal of Thrombosis and Haemostasis Open access 8 Dec 2017 40
9 Efficacy and safety of a VWF / FVIII concentrate (wilate®) in inherited von Willebrand disease patients undergoing surgical procedures Alok Srivastava, M. Şerban, Sylvia Werner et al. · Haemophilia Open access 27 Dec 2016 39
10 Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients Toshko Jelev Lissitchkov, Bella Madan, Claudia Djambas Khayat et al. · Journal of Thrombosis and Haemostasis Open access 30 Dec 2019 34
11 Five‐day stability of thawed plasma: solvent/detergent‐treated plasma comparable with fresh‐frozen plasma and plasma frozen within 24 hours Andrea Neisser‐Svae, Laurenz Trawnicek, Andrea Heger et al. · Transfusion Open access 29 Sep 2015 34
12 The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease Craig M. Kessler, Friedman Ken, Bruce A. Schwartz et al. · Thrombosis and Haemostasis 2011 31
13 Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial Toshko Jelev Lissitchkov, Bella Madan, Claudia Djambas Khayat et al. · Transfusion Open access 30 Nov 2017 24
14 von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease Robert Francis Sidonio, Ana Boban, Leonid Dubey et al. · Blood Advances Open access 18 Jan 2024 22
15 Efficacy and safety of fibrinogen concentrate for on‐demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency Claudia Djambas Khayat, Sunil Lohade, Fulton D’Souza et al. · Haemophilia Open access 16 Dec 2020 19
16 Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials Wolfgang Frenzel, Stefan Wietek, Tor‐Einar Svae et al. · International Journal of Clinical Pharmacology and Therapeutics Open access 10 Oct 2016 19
17 Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression John P. Feighner, Rudolph H. Ehrensing, Abba J. Kastin et al. · International Clinical Psychopharmacology Nov 2001 18
18 Overview of Subcutaneous Immunoglobulin 16.5% in Primary and Secondary Immunodeficiency Diseases Roger H. Kobayashi, Jiří Litzman, Syed Rizvi et al. · Immunotherapy Open access 6 Jan 2022 17
19 The role of von Willebrand factor in primary haemostasis under conditions of haemodilution I. Jalaer, Dimitrios A. Tsakiris, Barbara Solecka-Witulska et al. · Thrombosis Research 20 Jul 2017 17
20 Enzymatic Sequence Analysis of N-Glycans by Exoglycosidase Cleavage and Mass Spectrometry – detection of Lewis X Structures Christoph Kannicht, Detlef Grunow, Lothar Lucka · Humana Press eBooks Book chapter 29 Mar 2008 15
21 Thirty years of experience with solvent/detergent‐treated plasma for transfusion medicine Sabrina Racine‐Brzostek, Melissa M. Cushing, Michelle Gareis et al. · Transfusion Open access 21 Apr 2024 14
22 IVIG response in pediatric acute-onset neuropsychiatric syndrome correlates with reduction in pro-inflammatory monocytes and neuropsychiatric measures Isaac Melamed, Shamma Shakila Rahman, Heather Pein et al. · Frontiers in Immunology Open access 3 Oct 2024 13
23 Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens Sudhir Gupta, James DeAngelo, Isaac Melamed et al. · Journal of Clinical Immunology Open access 9 May 2023 11
24 Levison’s Textbook for Dental Nurses Carole Hollins · STOMATOLOGY EDU JOURNAL Open access 2020 11
25 Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies Roger H. Kobayashi, Jiří Litzman, Isaac Melamed et al. · Clinical & Experimental Immunology Open access 8 Oct 2022 10
26 The effect of treatment with a new antidepressant, INN 00835, on platelet serotonin uptake in depressed patients John P. Kelly, Gabriela Nicolau, Anna Redmond et al. · Journal of Affective Disorders Oct 1999 10
27 Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment John P. Feighner, Lev Sverdlov, Gabriela Nicolau et al. · The International Journal of Neuropsychopharmacology Open access Sep 2003 9
28 Are cardiac transplant patients more likely to have periodontitis? A case record study. Jan N. Lessem, Connie L. Drisko, Henry Greenwell et al. · PubMed Jul 2002 9
29 Principles for Stereoselective Separation of Chiral Drug Compounds Enantiomers and Diastereomers in Pharmaceuticals and Biopharmaceuticals Using Liquid Chromatography Niroja Vadagam, Sharath Babu Haridasyam, Narasimha Swamy Lakka et al. · Chirality Open access Feb 2025 8
30 Tolerability and safety of the intravenous immunoglobulin octagam®10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials Stefan Wietek, Daniel Svorc, Anette Debes et al. · Hematology Open access 11 Oct 2017 8
31 PSA assays Richard J. Ablin · The Lancet Oncology Sep 2000 7
32 Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease Michelle Sholzberg, Kate Khair, Hassan M. Yaish et al. · TH Open Open access Jul 2021 7
33 Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency Sudhir Gupta, Roger H. Kobayashi, Jiří Litzman et al. · Expert Review of Clinical Immunology Open access 8 Nov 2022 6
34 GROWTH AND NUCLEATION KINETICS IN BATCH CRYSTALLIZATION OF TRICLOSAN Yanan Zhou, Suphan Kovenklioglu · Chemical Engineering Communications 6 Apr 2004 6
35 ADAMTS13 content and VWF multimer and triplet structure in commercially available VWF/FVIII concentrates Christoph Kannicht, Claudine Fisseau, Werner Hofmann et al. · Biologicals 9 Dec 2014 6
36 Clinical pharmacokinetic studies with INN 00835 (Nemifitide), a novel pentapeptide antidepressant John P. Feighner, Gabriela Nicolau, H. Abajian et al. · Biopharmaceutics & Drug Disposition 2002 6
37 Use of objective efficacy criteria for evaluation of von willebrand factor/factor VIII concentrates Craig M. Kessler, Jerzy Windyga, Bruce A. Schwartz et al. · Blood Coagulation & Fibrinolysis 8 Feb 2012 6
38 Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review Keyvan Karkouti, Michelle Gareis, C Li et al. · Transfusion and Apheresis Science ReviewOpen access Apr 2025 5
39 Separation and Quantitative Estimation of Pharmacopeial Organic Impurities, Process‐Related Impurities, and Degradation Products of the Anti‐Schizophrenia Drug Clozapine in Pharmaceutical Formulations by Using Stability‐Indicating HPLC Method Abhishek Sharma, Pedavenkatagari Narayana Reddy, Bhujanga Rao Nagulancha et al. · Biomedical Chromatography Open access 10 Feb 2025 5
40 Free thiol groups in von Willebrand factor (VWF) are required for its full function under physiological flow conditions Barbara Solecka-Witulska, Christoph Weise, Birte Fuchs et al. · Thrombosis Research 10 Nov 2015 5
41 The state of the art of removal of prion proteins in SD-FFP, by specific prion affinity chromatography and its impact on the hemostatic characteristics of the product Andrea Neisser‐Svae, Jerard Seghatchian · Transfusion and Apheresis Science Open access 14 Feb 2015 5
42 Discriminant analysis to separate a study population by treatment subgroups in a pilot clinical trial with a new pentapeptide antidepressant (INN 00835) John P. Feighner, Lev Sverdlov, H. Abajian et al. · European Neuropsychopharmacology 2001 5
43 Comparison of systemic exposure to nemifitide following two methods of subcutaneous administration to healthy volunteers Gabriela Nicolau, John P. Feighner, Robert L. Stout et al. · Biopharmaceutics & Drug Disposition 30 Aug 2005 5
44 ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate® in the Observational ObsITI Study, Carmen Escuriola‐Ettingshausen, Vladimír Vdovin, N. I. Zozulya et al. · Blood 18 Nov 2011 3
45 Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis Cecil Reuben Ross, Savita Rangarajan, Mehran Karimi et al. · Blood 3 Dec 2015 3
46 Comparison of Pharmacokinetic Properties of Two VWF/FVIII Concentrates In Subjects with Inherited Von Willebrand Disease (VWD)- Results of a Prospective, Randomized, Crossover Study. Craig M. Kessler, Jerry Sherman Powell, Bruce A. Schwartz · Blood 19 Nov 2010 3
47 Two solvent/detergent‐treated plasma products with a different biochemical profile Andrea Neisser‐Svae, Andrea Heger · ISBT Science Series Open access 23 Jun 2016 3
48 NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre study Alok Srivastava, Angela Kanny, Florian Peter Länger et al. · BMJ Open Open access Oct 2025 2
49 Essentials of Dental Photography Popa Alexandra · STOMATOLOGY EDU JOURNAL Open access 2020 2
50 Relevance of Intact Von Willebrand Factor (VWF) Triplet Structure for VWF Function. Bruce A. Schwartz, Birte Fuchs, Christoph Kannicht et al. · Blood 19 Nov 2010 2

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.